To include your compound in the COVID-19 Resource Center, submit it here.

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients.

Surveyor Capital and Alexandria Venture Investments also participated in the financing. Separately, the California Institute

Read the full 446 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers